Innovations in the fields of medicine, artificial intelligence, robotics and sensors are finally giving a new life to medical technologies and are making human enhancement a reality.
Bionics, which is taking on human body dysfunctions and disabilities and, more globally, helping improve the wellness and lifespan of the world population, benefits from long-term drivers:
an ageing world population and a shortage of donated organs,
major technology breakthroughs leading to an impressive product pipeline,
an improving outlook for the reimbursement of bionic devices by insurers or health agencies.
The investment universe encompasses next-generation prosthetics, medical wearables and devices, surgical and medical robots, exoskeletons, 3D printing, synthetic biology and artificial intelligence all play a major role in the emergence of bionics.
Fixing our body dysfunctions:
Leveraging on life mechanisms:
The first artificial organ was designed in 1943 to replace a deficient kidney: a dialyzer.
Now a Microchip filter used in an artificial kidney is to be tested in humans by the end of 2017 and might keep a patient off dialysis.
Today, 60-70% of human body functionalities can be artificially performed as demonstrated by Frank, the bionic man Bertolt Meyer designed in 2013.
Still missing: digestive system, liver, skin and brain.
Medical technology innovations are made possible thanks to advances in:
Research is performed on extending Moore’s Law by optimizing chip technology. Quantum computing will further extend Moore’s law exponentially.
The price of bionic devices has been unsurprisingly high until now (between $50,000 and $150,000 for an eye or limb device and surgery).
Encouragingly, coverage by Medicare in the US seems to be heading in the right direction the health agency recently paid for a $144,000 bionic eye.
Declining costs and social welfare: a major catalyst for expanded health coverage.
According to the UN, the population aged 60 years or over will grow from 900M in 2015 to 1.4Bn in 2030, while the population >80 years old will grow from 125M to 201M. The bulk of the growth comes from Asia: 66% growth of people >60 years old.
Data source: United Nations (2015).
World Population Prospects: The Revision
Source: Various market research firms
Synthetic biology is the engineering of biology: the synthesis of complex, biologically based systems which display functions that do not exist in nature.
While products that utilize synthetic biology are yet to be commercialized, this market is set to literally explode in the next few years driven by demand for improved drugs and vaccines.
Key constraints are mostly ethics and bio-security/safety, as synthetic biology can be misused.
By accessing this website ("Site") and any of its pages you expressly agree that you have read, understood and agree to be bound by the terms and conditions and the legal information contained herein. If you do not agree to the terms and conditions below, you should exit the Site now.
Access to the information contained on this Site may be subject to legal and regulatory restrictions applicable to user (by reason of user’s place of residence or domicile, nationality, or for any other reason). Persons concerned by such prohibitions should not enter the Site.
The contents of this Site are provided for information purposes only. Nothing contained on this Site constitutes a solicitation, an offer or a recommendation to purchase or sell any product and/or may be construed as an offer, an invitation or solicitation to enter into any specific transaction or strategy. None of the products mentioned on this Site are available and term sheet shall not be distributed to any person or entity in any jurisdiction or country where such distribution or use would be contrary to any applicable law or regulation.
The collective investment scheme (hereinafter referred to as the "Fund") referred to on this Site is registered only in Luxembourg.
The products mentioned on the Site may not be offered, sold, assigned, or delivered, directly or indirectly at any time by any “US person”. In particular, the Fund mentioned on the Site has not been nor will be registered under the Securities Act of 1933 in the USA.
Although AtonRâ Partners believes that the information is reliable when posted on the Site, it makes no representation or guarantee that it is accurate or complete.
The information and opinions contained on the Site are subject to change without notice.
AtonRâ Partners shall not be responsible or liable for any loss or damage of any nature whatsoever (including direct, indirect, incidental or consequential) arising out of or in connection with the access to or the use of, or any inability to access or to use any information or data on this Site, including without limitation in the event of negligence.
Unless expressly stated otherwise, all information available on this Site is protected by copyright, with all rights reserved. The elements may be used freely for navigation purposes only and must expressly mention AtonRâ Partners in the event of reproduction, in whole or in part, of such elements in any form whatsoever, including in written or electronic form. No part of this Site may be distributed or transmitted without the express consent of AtonRâ Partners. Links to the Site or use of the content for advertising or commercial purposes is subject to the prior written consent of AtonRâ Partners.
AtonRâ Partners places great importance on data protection and makes every effort to safeguard the privacy of information. However, the Internet, like other electronic information and communication systems, cannot guarantee absolute security.
Use of this Site is subject to the laws of Switzerland without reference to any conflict of law principles. The courts of Geneva, Switzerland, shall have exclusive jurisdiction over any claims or disputes arising out of or in connection with the Site and its use.